Category Archives: Obviousness-Teaching Away

J Kyle Bass et al. (Petitioner) v. Fresenius Kabi USA, LLC (Patent Owner)

IPR2016-00254 U.S. Pat. No. 8,476,010B2 Final Written Decision (June 5, 2017) Brief Summary: Board found challenged claims of US 8,476,010B2 relating to formulations of the anesthetic propofol (2,6-diisopropylphenol) stored in containers having nonreactive, inert closures (sold as Diprivan) invalid for … Continue reading

Posted in Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away | Leave a comment

Coherus Biosciences Inc. v. Abbvie Biotechnology Ltd.

IPR2016-00172 U.S. Pat. No. 8,889,135B2 May 17, 2017 Final Written Decision (IPR granted May 17, 2016) Brief Summary: Final Written Decision after IPR finds claims 1-5 of Abbvie’s US 8,889,135B2 relating to Humira® unpatentable for obviousness. Summary: Coherus requested IPR … Continue reading

Posted in Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Obviousness-Teaching Away | Leave a comment

Nantkwest, Inc. v. Michele K. Lee (USPTO)

Docket No. 2015-2095 PROST, DYK, STOLL (D) May 3, 2017 Non-precedential Brief Summary: DC grant of SJ to PTO that claims to NK cell immunotherapy would have been obvious affirmed (“no material dispute that the combination…used here produced the invention … Continue reading

Posted in Obviousness, Obviousness-Teaching Away | Leave a comment

Michael Meiresonne v. Google, Inc.

Docket No. 2016-1755 (IPR2014-01188) PROST, LOURIE, MOORE March 7, 2017 Brief Summary: PTAB’s finding of no teaching away “supported by substantial evidence” (e.g., “nothing in either reference indicates that descriptive text would render Finseth’s rollover area inoperative for its intended … Continue reading

Posted in Obviousness, Obviousness-Teaching Away | Leave a comment